Showing results (71-80 of 83) with videos related to
Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2021
Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical TrialYukihide Kanemitsu, Kohei Shitara, Junki Mizusawa, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2024
Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018)Atsuo Takashima, Tetsuya Hamaguchi, Junki Mizusawa, et al.Journal of Gastroenterology|April 16, 2026
Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected pancreatic cancer: an exploratory analysis of the randomized clinical trial (JASPAC-01)Kazunaga Ishigaki, Yousuke Nakai, Kousuke Kashiwabara, et al.The Lancet. Gastroenterology & Hepatology|October 29, 2017
Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trialTetsuya Hamaguchi, Yasuhiro Shimada, Junki Mizusawa, et al.European Journal of Cancer (Oxford, England : 1990)|February 26, 2018
Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01)Yasuhiro Hagiwara, Yasuo Ohashi, Katsuhiko Uesaka, et al.Scientific Reports|June 23, 2021
PD-L1 upregulation is associated with activation of the DNA double-strand break repair pathway in patients with colitic cancerNaoya Ozawa, Takehiko Yokobori, Katsuya Osone, et al.Anticancer Research|August 19, 2007
Prediction of response to definitive chemoradiotherapy in esophageal cancer using positron emission tomographyHiroyuki Kato, Minoru Fukuchi, Tatsuya Miyazaki, et al.British Journal of Cancer|March 4, 2023
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trialYasutoshi Kuboki, Tetsuji Terazawa, Toshiki Masuishi, et al.Targeted Oncology|January 9, 2024
Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal CancerYu Sunakawa, Yasutoshi Kuboki, Jun Watanabe, et al.International Journal of Clinical Oncology|July 21, 2022
Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and RectumTakahiko Ito, Atsuo Takashima, Kentaro Yamazaki, et al.Pageof 9